Cite
Clarke NW, Ali A, Ingleby FC, et al. Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003. Ann Oncol. 2020;31(3):442doi: 10.1016/j.annonc.2020.01.002.
Clarke, N. W., Ali, A., Ingleby, F. C., Hoyle, A., Amos, C. L., Attard, G., Brawley, C. D., Calvert, J., Chowdhury, S., Cook, A., Cross, W., Dearnaley, D. P., Douis, H., Gilbert, D., Gillessen, S., Jones, R. J., Langley, R. E., MacNair, A., Malik, Z., Mason, M. D., Matheson, D., Millman, R., Parker, C. C., Ritchie, A. W. S., Rush, H., Russell, J. M., Brown, J., Beesley, S., Birtle, A., Capaldi, L., Gale, J., Gibbs, S., Lydon, A., Nikapota, A., Omlin, A., O'Sullivan, J. M., Parikh, O., Protheroe, A., Rudman, S., Srihari, N. N., Simms, M., Tanguay, J. S., Tolan, S., Wagstaff, J., Wallace, J., Wylie, J., Zarkar, A., Sydes, M. R., Parmar, M. K. B., James, N. D. (2020). Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003. Annals of oncology : official journal of the European Society for Medical Oncology, 31(3), 442. https://doi.org/10.1016/j.annonc.2020.01.002
Clarke, N W, et al. "Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003." Annals of oncology : official journal of the European Society for Medical Oncology vol. 31,3 (2020): 442. doi: https://doi.org/10.1016/j.annonc.2020.01.002
Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G, Brawley CD, Calvert J, Chowdhury S, Cook A, Cross W, Dearnaley DP, Douis H, Gilbert D, Gillessen S, Jones RJ, Langley RE, MacNair A, Malik Z, Mason MD, Matheson D, Millman R, Parker CC, Ritchie AWS, Rush H, Russell JM, Brown J, Beesley S, Birtle A, Capaldi L, Gale J, Gibbs S, Lydon A, Nikapota A, Omlin A, O'Sullivan JM, Parikh O, Protheroe A, Rudman S, Srihari NN, Simms M, Tanguay JS, Tolan S, Wagstaff J, Wallace J, Wylie J, Zarkar A, Sydes MR, Parmar MKB, James ND. Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003. Ann Oncol. 2020 Mar;31(3):442. doi: 10.1016/j.annonc.2020.01.002. Epub 2020 Jan 31. PMID: 32067690.
Copy
Download .nbib